International Stem Cell Corp. (OTCMKTS:ISCO) Short Interest Up 1,659.4% in December

International Stem Cell Corp. (OTCMKTS:ISCO) was the target of a significant increase in short interest during the month of December. As of December 15th, there was short interest totaling 563 shares, an increase of 1,659.4% from the November 30th total of 32 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average daily trading volume, of 8,461 shares, the short-interest ratio is currently 0.1 days. Based on an average daily trading volume, of 8,461 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the company’s stock are short sold.

International Stem Cell Stock Performance

Shares of ISCO stock opened at $0.13 on Friday. The firm’s 50-day moving average is $0.15 and its 200-day moving average is $0.14. The stock has a market cap of $1.05 million, a price-to-earnings ratio of -6.56 and a beta of 0.11. International Stem Cell has a 52-week low of $0.08 and a 52-week high of $0.27.

International Stem Cell Company Profile

International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.

In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations.